MDS Pharma Services Expands Presence in Latin America with Sao Paulo Office
28 Gennaio 2008 - 2:00PM
PR Newswire (US)
KING OF PRUSSIA, PA, Jan. 28 /PRNewswire-FirstCall/ -- MDS Pharma
Services, a leading provider of innovative drug discovery and
development solutions, has established an office in Sao Paulo,
Brazil, to provide expanded capabilities in global clinical trial
management. The new office joins nearly two dozen other MDS Pharma
Services late stage clinical trial management offices in 21
countries in Africa, Asia Pacific, Europe, Latin America and North
America. The opening of the Sao Paulo office is a clear indicator
of the growing importance of Latin America to the drug development
industry and of MDS Pharma Services' commitment to offer its
clients the advantages of conducting trials in the region. "Our new
office in Sao Paulo is a key component of our global expansion
strategy. It allows MDS Pharma Services to provide clients access
to a large diverse pool of clinical trial participants and abundant
healthcare resources, including more than 237,000 qualified
physicians and more than 46,000 health institutions," said MDS
Pharma Services President David Spaight. "Thanks to this excellent
infrastructure, clinical trials in Brazil have an impressive track
record of strong enrollment rates and good patient compliance and
retention. These are critical factors in allowing us to fulfill the
MDS Pharma Services brand promise to deliver high-quality, on-time
service to clients." In addition to the new office in Brazil, MDS
Pharma Services also offers clinical trial monitoring services from
Latin American offices in Buenos Aires, Argentina; Santiago, Chile;
Lima, Peru; and Mexico City, Mexico. Since 2002, the MDS Pharma
Services team in Latin America has conducted 33 global studies in
focus areas such as oncology, metabolic disorders, cardiovascular,
vaccines and infectious diseases. Drug development activity has
exploded in Brazil, which experienced a 1000 percent increase in
clinical trials between 1995 and 2000. It is estimated that 645
Phase I-IV clinical trials are currently taking place in Brazil.
While the incidence of heart disease, arthritis, cancer and
infectious diseases in Brazil is on par with the United States, a
greater percentage of the Brazilian population is treatment-naive,
providing a major source of potential adult and pediatric clinical
trial participants who are not taking prescription drugs that could
interact or interfere with the drug being tested. The Southern
Hemisphere location is another reason to include Brazil and other
Latin American countries in multi-center trials; these countries
experience summer when it is winter in the Northern Hemisphere,
allowing MDS Pharma Services to offer its clients year-round
testing of drugs for seasonally induced conditions such as
allergies and other respiratory indications. About MDS Pharma
Services MDS Pharma Services is committed to delivering quality
results on time. We offer a full spectrum of resources to meet the
drug discovery and development needs of the pharmaceutical and
biotechnology industries. With numerous facilities strategically
located around the world, we apply advanced scientific and
technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research,
early clinical research (bioequivalence, phases I-IIa) and
bioanalysis through to global clinical development (phases IIb-IV),
central lab and centralized cardiac services. For more information,
visit our website at http://www.mdsps.com/. MDS Pharma Services is
a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life
sciences company that provides market-leading products and services
that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,500 highly skilled people in 28 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. Source data - clinicaltrials.gov website (x) 645 Phase
I-IV studies currently taking place in Brazil
http://www.clinicaltrials.gov/ct2/results/map?term=Brazil&phase=0123&map=SA
DATASOURCE: MDS Pharma Services CONTACT: For Investors, Sharon
Mathers, (416) 675-6777 ext. 34721, ; For Media, Charlene McGrady,
(610) 239-7900 ext. 231,
Copyright